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Abstract
Background: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death
and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded),
placebo-controlled, experimental medicine study evaluated the safety, pharmacokinetics (PK), and preliminary
efficacy of GSK2982772, a RIPK1 inhibitor, in moderate to severe rheumatoid arthritis (RA).
Methods: Patients with moderate to severe RA who had received ≥12 weeks’ stable-dose conventional synthetic
disease-modifying antirheumatic drug (csDMARD) therapy were randomized (2:1) to GSK2982772 60 mg or placebo
orally 2 or 3 times daily for 84 days. Safety, PK, disease activity, joint damage, and pharmacodynamic (PD)
biomarkers were assessed at days 43 and 85.
Results: A total of 52 patients were randomized (placebo, 18; GSK2982772, 34). Adverse events (AEs) were reported
in 13 (72%) in patients in the placebo group (n = 3 b.i.d; n = 10 t.i.d.) and 20 (61%) in the GSK2982772 group (n = 3
b.i.d; n = 17 t.i.d.). All treatment-related AEs were mild/moderate, except one severe case of alopecia areata at day
49 and retinal vein thrombosis at day 66 (which led to withdrawal from the study) in patients receiving
GSK2982772 t.i.d. Disease Activity Score in 28 Joints–C-reactive protein (DAS28-CRP) scores, ACR20/50/70 response,
and rates of low disease activity and remission were similar between placebo and GSK2982772 arms.
Conclusions: These results suggest that inhibition of RIPK1 activity at the GSK2982772 exposure levels evaluated do
not translate into meaningful clinical improvement of RA.
Trial registration: ClinicalTrials.gov Identifier: NCT02858492. Registered 8 August 2016.
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Introduction
Rheumatoid arthritis (RA) is a chronic immune-
mediated inflammatory disease that affects synovial tis-
sue in multiple joints [1]. Despite available treatments,
there is still a significant unmet need for safe and toler-
able therapies, particularly in an oral formulation, that
lead to improved rates of clinical remission and in-
creased physical function in patients with moderate to
severe RA [2, 3].
Central to the pathogenesis of RA are interactions be-
tween innate immune cells (monocytes, dendritic cells,
mast cells) and adaptive immune cells (CD4+ T cells, B
cells, plasma cells) targeting the synovial membrane [1,
4]. Tumor necrosis factor (TNF) is a key cytokine that
drives chronic inflammation in RA [5, 6]. Binding of
TNF to its receptor, TNFR1, results in one of three po-
tential cellular outcomes: NF-κB activation, apoptosis, or
necrosis. NF-κB activation by agents such as pristine and
streptococcal cell wall have been associated with induc-
tion of rat arthritis [7, 8], and mice with myeloid cell-
specific deficiency of A20, a deubiquitinase negatively
regulating NF-κB signaling, spontaneously develop poly-
arthritis with typical features of RA [9].
RIPK1 blockade provides a potential new therapeutic
approach for immune-mediated inflammatory diseases.
RIPK1 is a critical kinase regulator of cell death (apop-
tosis and necroptosis) and proinflammatory cytokine
production downstream of numerous pathways and sig-
naling receptors, including the TNF family of cytokines,
ligands for toll-like receptor (TLR) 3/TLR4, and inter-
ferons [10]. Cell death by necroptosis is highly inflam-
matory due to the release of cellular contents and the
subsequent activation of pattern recognition receptor
signaling and innate immunity. RIP1 has dual roles as a
kinase and a scaffolding protein and serves as an up-
stream checkpoint for both cell death and survival [10].
The scaffolding function facilitates other immune pro-
cesses including TNF-mediated classical apoptosis and
NF-κB signaling [10–12].
RIPK1 inhibitors prevent TNF-dependent inflamma-
tion in multiple preclinical models (TNF shock, SHAR
PIN) [13, 14]. Mutations of HOIL, HOIP, or NEMO,
proteins in the linear ubiquitination chain assembly
complex, have been linked to activation of RIPK1 kinase
activity and result in TNF-dependent auto-inflammation
[10, 15, 16]; similar mutations in mice also result in in-
flammatory phenotypes that can be blocked with RIPK1
inhibitors [17]. In RA patients, expression of TNF and
its signaling intermediates, including RIPK1, have been
shown to be constitutively increased in peripheral blood
mononuclear cells compared to healthy controls [18].
RIPK1-mediated necroptosis has also been implicated
in increased cytokine production and inflammatory dis-
eases [19–21]. Inhibition of RIPK1 blocked necroptosis,
suppressed osteoclastogenesis, reduced synovial ex-
pression of proinflammatory cytokines, and decreased
arthritis progression in a collagen-induced mouse
model of RA [22].
GSK2982772 (5-Benzyl-N-[(3S)-5-methyl-4-oxo-2,3-
dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-car-
boxamide) (for chemical structure, see Additional file 1
Figure S1) is an oral selective inhibitor of RIPK1 that binds
an allosteric pocket of the RIPK1 domain and thus inhibits
RIPK1-mediated cell death and cytokine production in
preclinical models [23], and its safety and tolerability has
been demonstrated at doses up to 120mg b.i.d. in healthy
volunteers [24]. The current experimental medicine study
examined the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD), and preliminary efficacy of
GSK2982772 following 12 weeks of treatment in patients
with moderate to severe RA.
Methods
Study design
This multicenter, randomized, double-blind (sponsor-
unblinded), placebo-controlled experimental medicine
study was performed between October 17, 2016, and
October 22, 2018, in patients with moderate to severe
RA at 12 study centers in five countries (Germany, Italy,
Poland, Russia, and Spain). Participants were initially
assigned to either GSK2982772 60mg orally b.i.d. or pla-
cebo b.i.d. Following a protocol amendment, participants
were randomized to GSK2982772 60mg orally t.i.d. or
placebo t.i.d.
The primary objective was to assess the safety and tol-
erability of GSK2982772. Secondary objectives were to
quantify the plasma concentrations of GSK2982772 fol-
lowing administration 60 mg b.i.d. and t.i.d. In addition,
the impact of GSK2982772 on bone, cartilage, and syn-
ovial parameters (e.g., bone erosion, synovitis, osteitis,
and joint space narrowing); inflammatory biomarkers;
and clinical disease activity was investigated. The study
was approved by the ethics committee/institutional re-
view board at every participating institution and was
conducted according to the recommendations of Good
Clinical Practice and the Declaration of Helsinki. All pa-
tients provided written informed consent to participate
in the study.
Within 30 days of screening, eligible patients entered
an 84-day treatment period, which was followed by a 28-
day follow-up period. Patients were randomly assigned
in a 2:1 allocation ratio to receive either oral
GSK2982772 60 mg or placebo (b.i.d. per the initial
protocol or t.i.d. following approval of a protocol
amendment in all countries) for 84 days. Randomization
to treatment groups was via a central Interactive Tech-
nology System. The randomization number was assigned
from a randomization schedule generated prior to the
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start of the study, using validated internal software. A
data review committee (DRC) of the sponsor was un-
blinded for routine pharmacovigilance and internal
decision-making purposes regarding other studies with
GSK2982772. Informal review of DAS28-CRP data (and
inflammatory biomarkers and other endpoints if avail-
able) was conducted by the DRC after an appropriate
number of subjects completed day 43 (week 6). The for-
mal interim analysis, to assess futility as planned per the
protocol, was not conducted based on the recommenda-
tion by the DRC because, due to increased speed of re-
cruitment, all subjects had completed the treatment
phase before there was sufficient data to perform a futil-
ity assessment. An internal GSK Safety Review Team
(SRT) also reviewed blinded safety data, including clin-
ical laboratory parameters and adverse events, at appro-
priate intervals during the period of study conduct.
Treatment codes could be unblinded by the investigator
or treating physician only in the case of a medical emer-
gency or in the event of a serious medical condition,
when knowledge of the investigational product was es-
sential for the clinical management or welfare of the pa-
tient. GSK Global Clinical Safety and Pharmacovigilance
(GCSP) staff could unblind treatment codes in the event
of a serious adverse event (SAE).
Study population
Patients were enrolled if they were between 18 and 75
years old, had a confirmed diagnosis of RA according to
the revised 2010 American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
classification criteria [25], and had a disease duration of
≥12 weeks. Eligible patients had moderate to severe RA
as indicated by a swollen joint count ≥4 (28-joint count),
tender joint count ≥4 (28-joint count), and Disease Ac-
tivity Score in 28 Joints–C-reactive protein (DAS28-
CRP) ≥ 3.2 and CRP ≥ 5.0 mg/L at screening. Additional
inclusion criteria included naive status for any biologic
therapy for RA (previous exposure to a single anti-TNF
biologic was allowed if it was discontinued for reasons
other than primary nonresponse more than 8 weeks [or
five half-lives, whichever is longer] from first dose) and
at least 12 weeks of nonbiologic, conventional synthetic
disease-modifying antirheumatic drug (csDMARD) ther-
apy prior to screening. Participants were required to re-
main on a stable dose of csDMARD therapy throughout
the study.
Key exclusion criteria included the following: con-
firmed diagnosis of systemic lupus erythematosus, his-
tory of suicidal ideation or attempted suicide, active
infection or significant history of infection, surgery on
the joint chosen for biopsy or magnetic resonance im-
aging (MRI), history of other joint disease, and receipt of
intraarticular corticosteroids, arthrocentesis, or synovial
biopsy within 6 weeks of screening.
Full inclusion and exclusion criteria are included in
Additional file 1 Item S1.
Endpoints and assessments
The primary endpoint, safety, and tolerability of
GSK2982772 60mg b.i.d. or t.i.d. was assessed by moni-
toring AEs/SAEs, clinical laboratory tests, vital signs,
and 12-lead electrocardiogram (ECG).
Blood samples were collected pre-dose on days 8 and
43, and 1, 2, 4, and 6 h post-dose on days 1, 8, and 43 to
assess plasma concentrations of GSK2982772. Optional
synovial biopsy samples were collected on days 1 and 43
using standard procedures for patients who consented to
have biopsies collected [26]. Plasma and synovial biopsy
samples were analyzed for GSK2982772 using high-
performance liquid chromatography/tandem mass spec-
trometry (HPLC MS/MS).
Patient-reported outcomes included patient assess-
ment of joint pain, which was determined from a nu-
meric rating scale (0 [no pain] to 10 [most severe pain]).
Fatigue was assessed on the Functional Assessment of
Chronic Illness Therapy (FACIT) Fatigue Scale, a 13-
point fatigue questionnaire [27].
Clinical disease assessments included DAS28-CRP [28]
and ACR20/50/70 responses [29]. DAS28 is a composite
score, the components of which are tender/painful joint
count, swollen joint count, CRP level, and Patient’s Global
Assessment of Disease. ACR20/50/70 response measures
20%, 50%, or 70% improvement in tender and swollen
joint counts and in at least three of five core set measures:
patient and physician global assessments of disease activ-
ity, patient-reported pain, disability (measured with the
Health Assessment Questionnaire-Disability Index [HAQ-
DI]), and an acute-phase reactant.
To evaluate structural joint inflammation and damage,
gadolinium contrast-enhanced MRI of each patient’s
most affected hand and wrist was performed pre-dose
on days 1, 43, and 85. Synovitis, osteitis, and bone ero-
sion were scored using the Outcome Measures in
Rheumatology (OMERACT) Rheumatoid Arthritis MRI
Scoring System (RAMRIS) [30], and cartilage loss was
scored using the Cartilage Loss Scoring System (CAR-
LOS) [31]. All MRI images were scored centrally by a
single, expert radiologist blinded to visit order.
PD assessments in blood included mRNA expression and
biomarkers indicative of RA disease activity such as the
Vectra Disease Activity (DA) score and its components.
Data and statistical analysis
This was a safety study and therefore not powered to
test predefined differences in clinical efficacy or
biomarkers.
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The safety population consisted of all patients who re-
ceived at least one dose of study treatment (safety, effi-
cacy, and biomarker analyses). The PK populations for
GSK2982772 consisted of patients in the safety popula-
tion who received an active dose and for whom a
GSK2982772 PK sample was obtained and analyzed.
The primary safety and tolerability analysis was based
on review and display of adverse events (AEs), clinical la-
boratory values, vital signs, and ECG. For efficacy ana-
lyses, change from baseline data was analyzed using the
mixed model repeated measures approach accounting
for baseline, treatment, and visit. Biomarker endpoints
(except Vectra DA) were transformed before analyzing,
and their results are expressed as percentage changes.
Frequencies and standard errors were reported by treat-
ment group and visit for categorical endpoints. Add-
itional details on statistical analyses performed are
included in Additional file 1 Item S2.
Results
Disposition and demographics
A total of 52 patients were randomized (placebo, 18;
GSK2982772, 34). All 18 participants in the placebo
group (3 b.i.d., 15 t.i.d.) and 33 in the GSK2982772
group (5 b.i.d., 28 t.i.d.) received treatment and were in-
cluded in the safety population (Fig. 1). A total of 44
participants completed the study, 17 in the placebo
group (3 b.i.d., 14 t.i.d.) and 27 in the GSK2982772
group (5 b.i.d., 22 t.i.d.), and seven patients were with-
drawn (Fig. 1). Treatment compliance, calculated from
dispensed and returned tablet data, ranged from 95 to
100% for the placebo group, 96 to 100% for the
GSK2982772 60 mg b.i.d. group, and 70 to 104% for the
GSK2982772 60 mg t.i.d. group. Demographic character-
istics, disease severity, and concurrent medical condi-
tions showed no important differences between
treatment groups (Table 1). A slight difference in mean
baseline time since diagnosis was observed; however,
median values were similar.
Safety and tolerability
The frequency of AEs was similar across treatment
groups, with AEs reported in 13 (72%) patients in the
placebo group (100%, n = 3 for b.i.d.; 67%, n = 10 for
t.i.d.), and 20 (61%) patients in the GSK2982772 group
(60%, n = 3 for b.i.d., 61%, n = 17 for t.i.d.) (Table 2).
The most commonly reported AEs occurring in > 10% of
patients in either treatment group after combining the
b.i.d. and t.i.d. regimens were arthralgia (11% in the
combined placebo group and 6% in the combined
GSK2982772 group), headache (11% in the combined
placebo group and 3% in the combined GSK2982772
group), and peripheral swelling (11% in the combined
placebo group and 0% in GSK2982772 group). No AEs
in the combined GSK2982772 group occurred at a fre-
quency > 10%.
Two serious AEs were recorded in the GSK2982772
t.i.d. group (Table 2). One patient had multiple fractures
(tibia, upper limb, and ulna) resulting from a fall and
was withdrawn from treatment; the event was not con-
sidered related to study treatment. The other patient
had an event of severe visual disturbance and retinal
Fig. 1 Patient disposition. AE, adverse event; b.i.d., twice daily; t.i.d., three times daily
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vein thrombosis at day 66 that was considered re-
lated to study treatment by the principal investigator.
Confounders included the underlying indication of
RA and elevated cholesterol. The patient was with-
drawn from treatment and the study. Another sig-
nificant AE observed with GSK2982772 t.i.d. was a
case of moderate bronchitis that was considered re-
lated to study treatment and resulted in withdrawal
from the study.
Most treatment-related AEs were mild or moderate
in intensity (Table 2). All AEs and treatment-related
AEs in both placebo groups and the GSK2982772
b.i.d. group were mild or moderate; treatment-related
AEs classified as severe were observed in one patient
(4%) in the GSK2982772 t.i.d. group (alopecia areata
[onset at day 49, subject was not withdrawn nor
study medication amended] and retinal vein throm-
bosis [at day 66, resulted in withdrawal from the
study]).
Changes in hematology or clinical chemistry mea-
surements, ECGs, and vital signs were as expected for
the RA population and did not differ between placebo
and treatment groups. One patient with a history of
ventricular arrhythmia treated with GSK2982772 t.i.d.
had a clinically significant abnormal AE of sinus
arrhythmia in the final follow-up period (day 113). A
low percentage of patients experienced elevated
diastolic blood pressure (BP) (11% placebo, 9%
GSK2982772) or systolic BP (6% placebo, 9%
GSK2982772). No suicidality was reported during any
part of the study.
Table 1 Demographics and baseline characteristics (combined





Age, years (mean [SD])a 53.1 (7.28) 54.8 (10.72)
Sex, n (%)
Female 15 (83) 27 (82)
Male 3 (17) 6 (18)
BMI, kg/m2 (mean [SD]) 26.5 (4.35) 27.8 (4.48)
Ethnicity, n (%)
Hispanic or Latino 0 2 (6)
Not Hispanic or Latino 18 (100) 31 (94)
Race detail
American Indian or Alaskan native 0 1 (3)
White—White/Caucasian/European
Heritage
18 (100) 32 (97)
Time since formal diagnosis of RA, years
Mean (SD) 4.5 (3.27) 7.3 (7.24)
Median (min, max) 3.9 (0.6, 12.9) 4.4 (0.4, 31.1)
Time since onset of first musculoskeletal symptoms, years
Mean (SD) 6.6 (4.30) 9.5 (8.44)
Median (min, max) 5.5 (2.1, 14.4) 7.8 (0.6, 33.1)
Baseline medical conditions, n (%)
Cardiovascular risk factors 8 (44) 12 (36)
Other risk factors 11 (61) 19 (58)
Baseline (day 1) DAS28-CRP
Mean (SD) 5.4 (1.17) 5.2 (0.76)
Median (min, max)a 5.5 (1.9, 7.2) 5.1 (3.7, 7.1)
Baseline (day 1) CRP
Mean (SD) 19.8 (15.52) 14.4 (19.47)
Median (min, max)a 15.1 (1.3,
53.5)
9.4 (0.9, 98.2)
Baseline (day 1) RAMRIS
Synovitis
Mean (SD) 6.4 (4.70) 10.5 (4.97)
Median (min, max) 6.0 (0, 15) 10.0 (2, 20)
Bone erosion
Mean (SD) 11.5 (11.02) 16.5 (13.36)
Median (min, max) 7.0 (1, 40) 16.0 (1, 54)
Osteitis
Mean (SD) 5.3 (7.97) 6.4 (9.61)
Median (min, max) 1.0 (0, 28) 2.0 (0, 36)
Baseline (day 1) CARLOS
Mean (SD) 4.7 (9.32) 6.0 (9.06)
Median (min, max) 0 (0, 34) 1.5 (0, 36)
Table 1 Demographics and baseline characteristics (combined





Baseline (day 1) Vectra DA
Mean (SD) 50.8 (14.85) 50.9 (13.39)
Median (min, max) 51.5 (21, 69) 49.0 (29, 89)
Baseline (day 1) HAQ-DI
Mean (SD) 1.3 (0.79) 1.2 (0.61)
Median (min, max) 1.6 (0.0, 2.3) 1.4 (0.0, 2.1)
Baseline (day 1) FACIT-Fatigue
Mean (SD) 24.3 (9.92) 32.6 (10.18)
Median (min, max) 23.5 (8, 50) 32.5 (16, 52)
Data are expressed as mean (SD) unless otherwise stated
aMinimum values are outside the inclusion criteria because minimum values
for inclusion were assessed at screening, and these data represent data
collected at the baseline visit (day 1)
b.i.d., twice daily; BMI, body mass index; CARLOS, Cartilage Loss Scoring
System; CRP, C-reactive protein; DAS28-CRP, disease activity score for 28 joints
using CRP value; FACIT, Functional Assessment of Chronic Illness Therapy;
HAQ-DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid
arthritis; RAMRIS, Rheumatoid Arthritis MRI Scoring System; SD, standard
deviation; t.i.d., three times daily; Vectra DA, Vectra disease activity
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b.i.d. (n = 5)
GSK2982772 60mg
t.i.d. (n = 28)
GSK2982772 60mg
total (n = 33)
Any AE, n (%) 3 (100) 10 (67) 13 (72) 3 (60) 17 (61) 20 (61)
Any SAE, n (%) 0 0 0 0 2 (7) 2 (6)
Eye disorder
Retinal vein thrombosis 0 0 0 0 1 (4) 1 (3)
Injury, poisoning and procedural complications
Multiple fractures 0 0 0 0 1 (4) 1 (3)
Any AE leading to withdrawal, n
(%)
0 0 0 0 3 (11) 3 (9)
Infections and infestations




0 0 0 0 1 (4) 1 (3)
Injury, poisoning, and procedural complications
Multiple fractures (SAE) 0 0 0 0 1 (4) 1 (3)
Any treatment-related AEs, n (%) 3 (100) 2 (13) 5 (28) 1 (20) 6 (21) 7 (21)
Severe 0 0 0 0 1 (4) 1 (3)
Moderate 1 (33) 1 (7) 2 (11) 1 (20) 4 (14) 5 (15)
Mild 2 (67) 1 (7) 3 (17) 0 1 (4) 1 (3)
AEs occurring in > 10% of combined groups, n (%)
Musculoskeletal and connective tissue disorders
Arthralgia 2 (11) 2 (6)
Nervous system disorders
Headache 2 (11) 1 (3)
General disorders and administration site conditions
Peripheral swellinga 2 (11) 0
aIncluded swelling in the lower limbs and hands
AE, adverse event; b.i.d., twice daily; SAE, serious adverse event; t.i.d., three times daily
Table 3 Change from baseline in DAS28-CRP scores at day 85 (MMRM analysis)






Change from baseline at day 85
Placebo (b.i.d. and t.i.d.) 18 (15) −0.90 (0.31) (−1.51, −0.28)
GSK2982772 (b.i.d. and t.i.d.) 33 (27) −1.27 (0.23) (−1.73, −0.81) −0.38 (−1.15, 0.40)
Change from baseline at day 85 by treatment regimen
Placebo (b.i.d.) 3 (3) −1.00 (0.72) (−2.45, 0.46)
GSK2982772 (b.i.d.) 5 (5) −1.47 (0.56) (−2.60, −0.35) − 0.48 (−2.33, 1.37)
Placebo (t.i.d.) 15 (12) −0.87 (0.35) (−1.57, − 0.17)
GSK2982772 (t.i.d.) 28 (22) −1.23 (0.26) (−1.75, −0.71) −0.36 (− 1.23, 0.52)
b.i.d., twice daily; CI, confidence interval; DAS28-CRP, disease activity score for 28 joints using CRP value; LS mean, least squares mean; MMRM, mixed model
repeated measures; t.i.d., three times daily
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Clinical efficacy
Improvement in DAS28-CRP scores compared to baseline
was observed with both GSK2982772 and placebo at the
end of the treatment period (Table 3 and Fig. 2a, b). The
difference in least squares (LS) mean change from baseline
between GSK2982772 (combined data for the 60mg b.i.d.
and t.i.d. groups) and placebo was − 0.38 (95% confidence
interval [CI], − 1.15, 0.40) at day 85. No statistically signifi-
cant differences were observed between the GSK2982772
60mg b.i.d. and t.i.d. dosing regimens, or with
GSK2982772 treatment vs. placebo. Changes in DAS28-
CRP scores appeared to be driven by changes in tender
joint count, with no differences observed in CRP levels or
swollen joint counts between the placebo group and com-
bined treatment groups (Fig. 3a–c). Patient assessed joint
pain (Fig. 3d) as well as composite health outcomes in-
cluding change from baseline in the HAQ-DI [32] FACIT
fatigue mean score, clinical disease activity index, and sim-
ple disease activity index were similar in the GSK2982772
group and the placebo group (Fig. 4a–d).
Fig. 2 DAS28-CRP. a DAS28-CRP adjusted mean change from baseline and unadjusted box and whisker plot of unadjusted change from baseline
by treatment over time (combined b.i.d. and t.i.d. dosing). b DAS28-CRP adjusted mean change from baseline by dosing regimen. b.i.d., twice
daily; CRP, C-reactive protein; DAS28-CRP, disease activity score for 28 joints using CRP value; t.i.d., three times daily
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The proportion of patients achieving ACR20 (placebo
39%, GSK2982772 45%), ACR50 (placebo 17%,
GSK2982772 15%), and ACR70 (placebo 11%,
GSK2982772 12%) responses at day 85 were also similar
between the two groups (Additional file 1 Figure S2).
MRI
RAMRIS synovitis improved slightly in the GSK2982772
treatment group and showed some deterioration in the
placebo group (Fig. 5a). RAMRIS erosion scores deterio-
rated from baseline in the placebo group but not in the
GSK2982772 group (Fig. 5b); the difference from pla-
cebo in LS mean score was − 1.5 (95% CI, − 2.9, − 0.1) at
day 85. One patient in the GSK2982772 treatment group
who showed a large improvement in erosions may have
been a major contributor to the observed difference be-
tween the two groups (Fig. 5d). RAMRIS osteitis ap-
peared to show improvement with GSK2982772
treatment (Fig. 5c).
A change in CARLOS score from baseline was ob-
served in only one of 46 patients with postbaseline data.
This patient (GSK2982772 60 mg t.i.d.) showed a two-
point worsening of the score at both days 43 and 85.
Pharmacokinetics of GSK2982772
Overall median pre-dose plasma concentrations were
higher for the t.i.d. regimen than for the b.i.d. regimen
(~ 1.7-fold, ~ 10-fold, and ~ 5.5-fold higher on days 9,
43, and 85, respectively).
Trough synovial tissue samples were only available for
three patients, of whom two had quantifiable levels of
GSK2982772 at day 43. The GSK2982772 pre-dose con-
centration in synovial tissue was of a similar order of




The blood biomarker mean Vectra DA score at day 1
was 50.8 and 50.9 for placebo and GSK2982772 (com-
bined b.i.d. and t.i.d.) groups, respectively, indicating
high disease activity at baseline. No clinically relevant
changes from baseline were observed for either group at
day 43 or day 85 or between the two GSK2982772 dos-
ing groups (Additional file 1 Figure S3a). GSK2982772
treatment resulted in a small reduction over time for
S100A8/S100A9 (Additional file 1 Figure S3b). No major
Fig. 3 Clinical efficacy parameters (combined b.i.d. and t.i.d. dosing). Adjusted mean change from baseline and unadjusted box and whisker plot
of unadjusted change from baseline by treatment over time. a C-reactive protein. b Swollen joint count (28). c Tender joint count (28). d Patient
assessment of joint pain. b.i.d., twice daily; CRP, C-reactive protein; t.i.d., three times daily
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changes were observed for other examined biomarkers
(Additional file 1 Table S1). Because of the small num-
ber of synovial biopsy samples, biomarker data in syn-
ovial tissue were not available for comparison with
blood data.
Discussion
This was the first study of an RIPK1 inhibitor in patients
with RA. Repeat doses of GSK2982772 60mg b.i.d. or t.i.d.
administration up to 85 days were well tolerated with no
safety signals observed in patients with moderate to severe
RA. No differences were noted in AEs between active
treatment and placebo groups. Most AEs were mild or
moderate, and no differences were noted between the
b.i.d. and t.i.d. doses of GSK2982772. The study did not
show any significant difference between GSK2982772 and
placebo treatment for changes in disease activity, radio-
logical progression, or inflammatory markers.
In the current study, the b.i.d. and t.i.d. regimens of
GSK2982772 were similar with respect to safety, efficacy,
and PD assessments. However, the study was not pow-
ered to investigate differences in DAS28-CRP responses
between the two doses, and the numbers in the b.i.d. co-
hort were too small for any strong conclusions to be
drawn. Higher GSK2982772 exposure levels were
achieved with 60 mg t.i.d. dosing than with b.i.d. dosing.
Although drug levels were detectable in two of only
three available synovial tissue samples, concentrations of
GSK2982772 in synovial tissue appeared to be of a simi-
lar order of magnitude to the concentrations in plasma
indicating that GSK2982772 can penetrate into the effect
site compartment.
Changes in disease activity from baseline, as measured
by DAS28-CRP and ACR20/50/70 responses, improved
with GSK2982772, but did not differ significantly com-
pared to placebo. The placebo effect observed in our
study was in line with that noted in other studies in pa-
tients with moderate to severe RA [33–43]. However, in
contrast to our study, other small molecule studies (i.e.,
tofacitinib, baricitinib, upadacitinib, filgotinib, fenebruti-
nib) showed a significant improvement in disease activity
vs. placebo [33–43].
GSK2982772 treatment resulted in a small improve-
ment in the RAMRIS synovitis score compared to
Fig. 4 Health outcomes measures (combined b.i.d. and t.i.d. dosing). Adjusted mean change from baseline and unadjusted box and whisker plot
of unadjusted change from baseline by treatment over time. a HAQ-DI. b FACIT fatigue. c Clinical disease activity index (CDAI). d Simple disease
activity index (SDAI). b.i.d., twice daily; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire-
Disability Index; t.i.d., three times daily
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placebo; however, the difference in means may have
been largely influenced by two patients, with most pa-
tients showing a similar response across treatment
groups. Bone erosion worsened in the placebo group
over the study duration, with little change in the
GSK2982772 group, but one patient in the
GSK29822772 group, who showed a large improvement,
may have contributed to much of the mean difference
between treatment groups. Alternatively, this finding
may support other studies that have suggested a poten-
tial role for RIPK1 inhibition in the suppression of oste-
oclastogenesis [22, 44].
A mean Vectra DA score of ~ 51 at baseline in both
treatment groups was indicative of the high overall dis-
ease activity of the recruited patients at baseline. The
overall Vectra DA score remained unchanged in both
groups over time. Minor improvements in some bio-
markers were observed in the active treatment group,
but these changes did not translate into a greater clinical
benefit.
In conclusion, this study suggested that administration
of GSK2982772 60 mg b.i.d. or t.i.d. for 84 days in pa-
tients with moderate to severe RA was safe and well tol-
erated. However, inhibition of RIPK1 activity with
GSK2982772 did not lead to differences in measures of
efficacy and joint damage compared with placebo.
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Fig. 5 RAMRIS parameters. Adjusted mean change from baseline and unadjusted box and whisker plot of unadjusted change from baseline by
treatment over time. a Synovitis. b Bone erosion. c Osteitis (combined b.i.d. and t.i.d. dosing). d Cumulative plot probability of change from
baseline in bone erosion total score on day 85. b.i.d., twice daily; RAMRIS, Rheumatoid Arthritis MRI Scoring System; t.i.d., three times daily
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